Condition
Herpes Simplex Infections
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02579083Phase 1Completed
Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV
NCT02270099CompletedPrimary
Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects
NCT01429311Completed
Interferon Responses in Eczema Herpeticum
NCT02715752CompletedPrimary
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
Showing all 4 trials